目的 探討他莫昔芬聯(lián)合米非司酮對(duì)圍絕經(jīng)期子宮肌瘤的療效及血清性激素水平的影響。方法 選取2012年3月-2017年3月在寶雞市婦幼保健院診治的97例圍絕經(jīng)期子宮肌瘤患者，按治療方法分成對(duì)照組、觀察組，分別47、50例。對(duì)照組進(jìn)行米非司酮治療，觀察組在此基礎(chǔ)上聯(lián)合他莫昔芬治療，兩組均治療6個(gè)月。比較兩組治療前后瘤體體積、血清性激素水平的變化，比較兩組臨床療效、治療期間不良反應(yīng)的發(fā)生情況。結(jié)果 治療前兩組患者瘤體體積間無顯著差異；兩組治療后瘤體體積均明顯減小，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且觀察組明顯小于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組的臨床療效總有效率間無顯著差異，但觀察組顯效率更高（P<0.05）。治療前兩組患者血清FSH、LH、E、P水平間無顯著差異；治療后兩組的血清FSH、E、P水平均顯著降低同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且觀察組顯著低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組不良反應(yīng)發(fā)生率間比較無顯著差異。結(jié)論 他莫昔芬聯(lián)合米非司酮對(duì)圍絕經(jīng)期子宮肌瘤的療效確切，安全可靠，可顯著減少瘤體體積、降低血清FSH、E、P水平，值得臨床推廣應(yīng)用。

Objective To investigate the effect of tamoxifen combined with mifepristone on the efficacy and serum sex hormone levels of uterine fibroids in menopausal women. Methods Selected 97 patients with uterine fibroids in menopausal women in our hospital from March 2012 to March 2017. All patients were divided into control group and observation group by treatment method, 47, 50 cases respectively. The control group was treated with mifepristone. The observation group was given tamoxifen on the basis of the control group. The changes of tumor volume and serum sex hormone levels before and after treatment were compared between two groups. The clinical efficacy and the incidence of adverse reactions during the treatment between two groups were compared. Results:There was no significant difference between the two groups of tumor volume before treatment. The tumor volume of both groups were significantly decreased after treatment (P<0.05), and the observation group was significantly smaller than the control group (P<0.05). There was no significant difference between the two groups in the total effective rate, but the effective rate in the observation group was significantly higher than that in the control group (P<0.05). There was no significant difference in serum FSH, LH, E, P levels between the two groups before treatment. Serum FSH, E, P levels in the two groups were significantly decreased after treatment (P<0.05), and the observation group was significantly lower than the control group (P<0.05). The incidence of adverse reactions between the two groups showed no significant difference. Conclusions Tamoxifen combined with mifepristone on peri-menopausal uterine fibroids curative effect is accurate, safe and reliable, can significantly reduce the volume of the tumor, lower serum FSH, E, P levels, worthy of clinical application.